Zenas BioPharma, Inc. — Form 8-K
Filed November 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Zenas reported Q3 2026 results with $647.1M in cash (2.5x company market cap), $10M revenue from Bristol-Myers Squibb milestone, and net loss of $108.9M. Key catalysts: FDA assigned PDUFA target date of May 27, 2027 for obexelimab BLA in IgG4-RD; EMA validated MAA submission; Phase 2 SunStone SLE trial topline results expected Q4 2026; ZB021 Phase 1 data expected Q4 2026. R&D expenses doubled YoY to $58.5M; G&A nearly doubled to $27.4M; $27.5M in milestone payments (InnoCare $25M, Xencor $2.5M).
Why this rating
Obexelimab regulatory path is de-risked with near-term FDA decision; strong cash runway through Q2 2029 supports commercialization. For $259M company, $647M cash and multiple pipeline catalysts are material. Near-term revenue upside if approved.
Tradability signal
NO TRADE
No trade: positive news with only -1.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.53% over 4 hrs, n=325). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $27.80 | +10 min · unknown $27.65 ▼ 0.56% | +30 min · unknown $27.86 ▲ 0.20% | +1 hr · unknown $27.72 ▼ 0.31% | +4 hrs · unknown $26.78 ▼ 3.69% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.